[Disclosure] Celltrion (068270) Secures Final U.S. FDA Approval for ‘Eydenzelt’ (Eylea Biosimilar)

Source: Financial Supervisory Service (DART) / 2025-10-10

Disclosure Type: Matters of Major Management Decisions Related to Investment Judgment

💡 3-Second Summary

Celltrion has obtained final U.S. FDA approval for ‘Eydenzelt (CT-P42)’, a biosimilar of the blockbuster ophthalmic drug Eylea, paving the way to enter the world’s largest healthcare market.

📊 1. [Key Disclosure Details and Major Financial Figures Summary]

• Product Name: Eydenzelt (Project Name: CT-P42, Active Ingredient: Aflibercept – Eylea Biosimilar)
• Target Indications:
  • Neovascular (Wet) Age-Related Macular Degeneration (Wet-AMD)
  • Macular edema following retinal vein occlusion
  • Diabetic macular edema
  • Diabetic retinopathy
• Approval Timeline:
  • Application Date: June 29, 2023 (Local Time)
  • Approval Date: October 2, 2025 (Local Time)
  • Date of Fact Confirmation (Official Receipt): October 3, 2025
• Regulatory Authority: U.S. Food and Drug Administration (FDA)
• Future Commercialization Plan: Celltrion plans to distribute and sell Eydenzelt across the United States through its local U.S. subsidiary.

📈 2. [Expert View: What This Disclosure Means for Investors]

• Fundamental Impact & Market Scale: This FDA approval marks a significant strategic expansion for Celltrion, extending its U.S. biosimilar portfolio from autoimmune and oncology treatments into the ophthalmic sector. Since the original product, Eylea, is a blockbuster treatment with massive global annual sales, securing access to the U.S. market could drive long-term revenue diversification and bolster Celltrion’s fundamental growth.
• Commercialization Risks & Factors: Although securing regulatory approval is a major milestone, Celltrion may face intense competition from other global pharmaceutical firms launching competing biosimilars. In addition, the speed of market penetration under its U.S. direct sales model and initial marketing expense allocation may impact near-term profitability.
• Unstated Details: Investors should note that this disclosure does not specify concrete launch dates, pricing strategies, insurance formulary listing status, or projected sales guidance, leaving future financial impacts subject to execution variables.

📝 Editor’s Comment (by K-STOCK Editor)

After a rigorous 2-year and 3-month regulatory process, Celltrion has successfully entered the highly lucrative U.S. ophthalmic biosimilar space. As the company continues its regulatory push globally, this FDA approval stands as the most critical pillar. Eydenzelt’s launch will serve as a major test for Celltrion’s established direct-sales infrastructure in the U.S. The key variable to monitor going forward is how quickly the company can secure preferred status on major insurance formularies to capture meaningful market share.

📢 Disclaimer & Source Information

Source: This content is structured and newly written based on the official data submitted to the Financial Supervisory Service (DART).

Investment Risk Advisory: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.

Inquiries: For compliance queries or copyright requests, please contact ksb220805@gmail.com.